Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance vs Observation After R2 Induction in MZL (ROMA)
NCT07654465Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in marginal zone lymphoma (MZL), sponsored by Sun Yat-sen University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07654465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654465.